# US 2011/0301115 A1 · Methods of Treating Subclinical Sun Damage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301115 A1
- Document ID: US20110301115A1
- Status: Published application
- Kind: A1
- Application number: 13/008,539
- Filed: 2011-01-18
- Published: 2011-12-08
- Earliest claimed: 2010-06-07
- Inventors: Robert K. Ilowite
- Web page: https://patentgrep.com/patent/US20110301115A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of treating subclinical sun damage and of inducing a chemocytotoxic response in skin. Methods of treating subclinical sun damage include the steps of: topically administering to skin of a patient a composition comprising a chemocytotoxic agent in an amount effective to induce erythema, scaling, crusting, or combinations thereof and resolve at least a portion of the subclinical sun damage, where the skin has a condition of no clinical sign of sun damage and the patient was not previously treated for actinic keratosis or nonmelanoma skin cancer. The chemocytotoxic agent can comprise a fluorinated pyrimidine antimetabolite such as 5-fluorouracil (FU), 5-fluorouridine (FUR), 5-fluorouridine-5′-monophosphate (FUMP), 5-fluorodeoxyuridine (FUdR), 5-fluorodeoxyuridine-5′-monophosphate (FdUMP), or combinations thereof.

## Claims

### Claim 1

A method of treating subclinical sun damage, the method comprising:
topically administering to skin of a patient a composition comprising a chemocytotoxic agent in an amount effective to induce erythema, scaling, crusting, or combinations thereof and resolve at least a portion of the subclinical sun damage;
wherein the skin has a condition of no clinical sign of sun damage and the patient was not previously treated for actinic keratosis or nonmelanoma skin cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chemocytotoxic agent comprises a fluorinated pyrimidine antimetabolite.

### Claim 3 (depends on 2)

The method of claim 2, wherein the fluorinated pyrimidine antimetabolite comprises: 5-fluorouracil (FU), 5-fluorouridine (FUR), 5-fluorouridine-5′-monophosphate (FUMP), 5-fluorodeoxyuridine (FUdR), 5-fluorodeoxyuridine-5′-monophosphate (FdUMP), or combinations thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the chemocytotoxic agent comprises 5-fluorouracil.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition is applied in a dosage in a range of 0.01 to 1 mg/cm2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is administered in a cycle of therapy that in the range of two to four weeks.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered once or twice daily during the cycle of therapy.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cycle of therapy is repeated at least once on a substantially annual basis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients.

### Claim 10

A method of treating subclinical sun damage, the method comprising:
topically administering to skin in need thereof a composition consisting essentially of 5-fluorouracil and one or more pharmaceutically acceptable carriers or excipients in an amount effective to induce erythema, scaling, crusting, or combinations thereof and resolve at least a portion of the subclinical sun damage;
wherein the skin has a condition of no clinical sign of sun damage, no previous actinic keratosis, and no previous nonmelanoma skin cancer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is administered in a cycle of therapy that is in the range of two to four weeks.

### Claim 12 (depends on 10)

The method of claim 10, wherein the composition is administered once or twice daily during the cycle of therapy.

### Claim 13 (depends on 10)

The method of claim 10, wherein the cycle of therapy is repeated at least once on a substantially annual basis.

### Claim 14 (depends on 10)

The method of claim 10, wherein the composition comprises 5-fluorouracil in an amount in the range of 0.25 to 10% by weight.

### Claim 15 (depends on 14)

The method of claim 14, wherein the composition comprises the 5-fluorouracil in an amount in the range of 0.5 to 5% by weight.

### Claim 16

A method of inducing a chemocytotoxic response in skin having a condition of no clinical sign of sun damage, no previous actinic keratoses, and no previous nonmelanoma skin cancer, the method comprising:
topically administering to the skin having the condition an effective amount of a composition comprising a chemocytotoxic agent during a cycle of therapy that is in the range of two to four weeks; and
observing the skin for the response;
wherein the composition is administered once or twice daily during the cycle of therapy, which is repeated at least once on a substantially annual basis.

### Claim 17 (depends on 16)

The method of claim 16, wherein the chemocytotoxic agent comprises a fluorinated pyrimidine antimetabolite.

### Claim 18 (depends on 16)

The method of claim 16, wherein the fluorinated pyrimidine antimetabolite comprises 5-fluorouracil.
